Payment overview · 2025
General Payments
$52,382.04
199 reported records · 31 companies
Healthcare provider profile · identity verified
Sumana Gangi, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · MESQUITE, TX · NPI 1487679213
Verified facts
What the public records show
CMS Open Payments records show Sumana Gangi, M.D received $52,382.04 in general payments during 2025 across 199 reported records.
Lilly USA, LLC accounted for 83.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Rybelsus, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Prolia by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Unithroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tresiba by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43,504.84 | 83.0% | 73 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5,600.00 | 10.7% | 7 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $594.92 | 1.1% | 2 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $408.97 | 0.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $349.11 | 0.7% | 12 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $217.12 | 0.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $190.56 | 0.4% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$180.71 | 0.3% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $170.41 | 0.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $160.90 | 0.3% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $147.49 | 0.3% | 11 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $95.51 | 0.2% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $83.07 | 0.2% | 4 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $73.13 | 0.1% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $69.18 | 0.1% | 6 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $61.86 | 0.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.45 | 0.1% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $54.61 | 0.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.61 | 0.1% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $47.08 | 0.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.25 | 0.1% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.59 | 0.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.73 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $25.15 | 0.1% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.82 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.96 | 0.0% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.90 | 0.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.60 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.75 | 0.0% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $13.73 | 0.0% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $12.03 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,175.00 | 41 |
| Food and Beverage | $2,761.41 | 146 |
| Travel and Lodging | $1,445.63 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41,721.21 | 67 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $6,746.61 | 11 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $594.92 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $255.41 | 8 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $217.12 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $170.41 | 8 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $153.28 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $147.49 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $109.55 | 7 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $95.51 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.70 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $91.02 | 7 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $83.07 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $81.01 | 3 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $73.13 | 4 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $73.13 | 4 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $73.13 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $69.18 | 6 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $69.18 | 6 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $69.18 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.44 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $62.61 | 4 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $61.86 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.45 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $54.61 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.61 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.25 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $42.59 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $12.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 325 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 325 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 611 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
191 | 51 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
77 | 50 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
325 | 115 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
325 | 115 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
325 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
325 | 115 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
325 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
216 | 80 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
611 | 181 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1163 | 354 |
| Ozempic | Semaglutide | 611 | 181 |
| Metformin Hcl | Metformin Hcl | 493 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 127 |
| Glimepiride | Glimepiride | 335 | 105 |
| Jardiance | Empagliflozin | 325 | 115 |
| Mounjaro | Tirzepatide | 325 | 90 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 261 | 117 |
| Tresiba Flextouch U-100 | Insulin Degludec | 259 | 101 |
| Gabapentin | Gabapentin | 224 | 85 |
| Farxiga | Dapagliflozin Propanediol | 220 | 67 |
| Trulicity | Dulaglutide | 216 | 80 |
| Methimazole | Methimazole | 207 | 59 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 196 | 95 |
| Synthroid | Levothyroxine Sodium | 191 | 51 |
| Novolog Flexpen | Insulin Aspart | 171 | 82 |
| Simvastatin | Simvastatin | 171 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 69 |
| Lisinopril | Lisinopril | 160 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 40 |
| Humalog Kwikpen U-100 | Insulin Lispro | 132 | 69 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 122 | 39 |
| Losartan Potassium | Losartan Potassium | 121 | 39 |
| Metformin Hcl Er | Metformin Hcl | 108 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 34 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 91 | 38 |
| Fenofibrate | Fenofibrate | 79 | 16 |
| Prolia | Denosumab | 77 | 50 |
| Carvedilol | Carvedilol | 76 | 19 |
| Levemir Flexpen | Insulin Detemir | 76 | 45 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 76 | 32 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 73 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 72 | 26 |
| Humalog | Insulin Lispro | 67 | 25 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 27 |
| Liothyronine Sodium | Liothyronine Sodium | 65 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 20 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 62 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 22 |
| Droplet Pen Needle | Pen Needle, Diabetic | 60 | 22 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 59 | 24 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 59 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 19 |
| Furosemide | Furosemide | 55 | 17 |
| Calcitriol | Calcitriol | 54 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 17 |
| Hydrocortisone | Hydrocortisone | 52 | 13 |
| Novolog | Insulin Aspart | 50 | 17 |
| Rybelsus | Semaglutide | 49 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Omeprazole | Omeprazole | 45 | 16 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 17 |
| Potassium Chloride | Potassium Chloride | 42 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 11 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 39 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Insulin Lispro | Insulin Lispro | 38 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 14 |
| Glipizide | Glipizide | 35 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 11 |
| Pregabalin | Pregabalin | 35 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 14 |
| Allopurinol | Allopurinol | 34 | 11 |
| Cabergoline | Cabergoline | 34 | 11 |
| Teriparatide | Teriparatide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 31 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Armour Thyroid | Thyroid,pork | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Unithroid | Levothyroxine Sodium | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 20 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Tresiba | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Zoledronic Acid | Zoledronic Acid/Mannitol-Water | 15 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52,382.04 · 199 records | Lilly USA, LLC | AFREZZA, CRENESSITY, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, Fibroscan, Flector, INTELLIS ADAPTIVESTIM, ISTURISA, JARDIANCE, Kerendia, Korlym, Licart, MINIMED 780G, MOUNJARO, Omnipod, Ozempic, PROLIA, RECORLEV, REZDIFFRA, Rybelsus, SOMAVERT, TEPEZZA, TWIIST, TZIELD, Tirosint, Tlando, Tymlos, UNITHROID, Veozah, Wegovy, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error